Objective: Antihistamines are excellent candidates for drug repositioning in cancer treatment as they are safe drugs that are well tolerated and have minimal side effects. We aimed to demonstrate the effects of Pheniramine Hydrogen Maleate (FHM) on non-small cell lung carcinoma (NSCLC) in the context of drug repositioning. Method: The similarity of FHM to other cancer drugs in the context of drug repositioning in NSCLC treatment was investigated with the web server DrugCentral2023.org. The possible apoptotic effects of the drug and the interaction between FasLR and FHM in the extrinsic pathway were evaluated in silico. Findings: FHM, which has very low toxicity, is similar to cancer drugs in the context of drug repositioning. According to the analysis of molecular docking results, there are three different chemical interactions. Conclusion: It is thought that the possible effects of FHM, which has very low toxicity, will lead to new in vitro and in vivo studies in the context of drug repositioning.